SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ekman B.)
 

Sökning: WFRF:(Ekman B.) > Glimelius B > Early and intermedi...

Early and intermediate stage Hodgkin's lymphoma - Report from the Swedish National Care Programme

Molin, D. (författare)
Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Onko
Enblad, G. (författare)
Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Onko
Gustavsson, Anita (författare)
Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Department of Oncology, Lund, Sweden
visa fler...
Ekman, T. (författare)
Department of Oncology, Gothenburg, Sweden
Erlanson, M. (författare)
Department of Oncology, Umeå, Sweden
Haapaniemi, E. (författare)
Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Onko
Glimelius, B. (författare)
Uppsala universitet,Karolinska Institutet,Department of Oncology, Uppsala, Sweden,Institutionen för onkologi, radiologi och klinisk immunologi,Onko
visa färre...
 (creator_code:org_t)
2003-02-26
2003
Engelska.
Ingår i: European Journal of Haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 70, s. 172-
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • In Sweden a National Care Programme provides treatment principles for Hodgkin's lymphoma (HL) since 1985, for early and intermediate stages often less extensive than international recommendations. The purpose is to evaluate long-term results of these principles. A total of 308 patients (167 men and 141 women), 17-59 yr old (median 31), diagnosed during 1985-92, pathological stage (PS) I-III1A and I-IIB and clinical stage (CS) I-IIA, mean follow-up 8.8 yr, were studied. Staging laparotomy was recommended in CS IIA. Recommended treatment was mantle or mini-mantle radiotherapy (RT) alone in CS IA, and PS I-IIA and subtotal nodal irradiation in PS III1A if the disease was not bulky. Patients in PS I-IIA and III1A with bulky disease, and PS I-IIB received one cycle of mechlorethamine, vincristine, prednisone, procarbazine/doxorubicin, bleomycin, vinblastine, lacarbazine (MOPP/ABVD) before irradiation. The remaining patients received three to four cycles of MOPP/ABVD with RT to bulky disease. Relapse-free (RFS), Hodgkin specific (HLS), and overall survival (OS) at 10 yr were 74%, 92% and 85%. In the individual stages, RFS ranged from 53% (PSIII1A) to 90% (PS IA). RFS (P = 0.006), HLS, and OS were significantly better in patients treated with chemotherapy compared with those treated with RT alone, especially in patients with bulky disease (P = 0.0005). The international prognostic score did not provide any prognostic information. The OS rates are in agreement with results from international centres during that time. The recommended treatment was sufficient to produce the desired results of <20-30% recurrences, except in PS III1A. Most relapses could be salvaged. Patients with risk factors treated with one MOPP/ABVD and RT had an excellent outcome, superior to those without risk factors treated with RT alone. These results favour the trend to treat early and intermediate stages with a short course of chemotherapy followed by limited RT.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Early stage
Hodgkin's lymphoma
Intermediate stage
Prognosis
Treatment
NATURAL SCIENCES
NATURVETENSKAP

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy